Norwegian version of this page

Functional immunogenetics

We study coeliac disease to understand the interplay between genetic and environmental factors in chronic inflammatory disorders.

Our group is striving to understand what happens when the body's defense from disease, the immune system, directly or indirectly causes harm to the body.

Coeliac disease, rheumatoid arthritis, type 1 (insulin dependent) diabetes, and multiple sclerosis are examples of autoimmune disorders of a chronic inflammatory nature.

We are concentrating on coeliac disease as a model to understand the molecular mechanisms leading to chronic inflammatory disease.

Research in the group has lead to a better understanding of the molecular basis of coeliac disease, but has also revealed general principles of immune regulation that are applicable to other immune mediated disorders.

The research group is part of the K.G. Jebsen Coeliac Disease Research Centre. In the period 2007 - 2017 the research group was part of the Centre for Immune Regulation (CIR), a Centre of Excellence established by the Research Council of Norway.

The research group is located at the Department of Immunology at OUS-Rikshospitalet and is part of the University of Oslo and the Oslo University Hospital.


  • B cells and the auto-antibody response of coeliac disease.
  • How certain variants of HLA molecules predispose to disease development.
  • Characterisation of how T cells recognise gluten protein, the dietary antigen precipitating coeliac disease.
  • How transglutaminase (TG) 2 mediated post-translational protein modification increases antigenicity.

Representative papers

  • Sollid, LM. Epstein-Barr virus as a driver of multiple sclerosis. Science Immunology. 2022. doi: 10.1126/sciimmunol.abo7799. Epub 2022 Apr 1.
  • Iversen R, Amundsen SF, Kleppa L, du Pré MF, Stamnaes J, Sollid LM: Evidence that pathogenic transglutaminase 2 in celiac disease derives from enterocytes. Gastroenterology. 2020. doi:
  • Iversen R, Sollid LM. Autoimmunity provoked by foreign antigens. Science. 2020 Apr 10;368(6487):132-133. doi: 10.1126/science.aay3037. PubMed PMID: 32273455. Full text. PDF.
  • du Pré MF, Blazevski J, Dewan AE, Stamnaes J, Kanduri C, Sandve GK, Johannesen MK, Lindstad CB, Hnida K, Fugger L, Melino G, Qiao SW, Sollid LM. B cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2. J Exp Med. 2020 Feb 3;217(2). doi: 10.1084/jem.20190860. PubMed PMID: 31727780. 
  • Christophersen A, Risnes LF, Dahal-Koirala S, Sollid LM. Therapeutic and diagnostic implications of T cell scarring in celiac disease and beyond. Trends Mol Med. 2019 Oct;25(10):836-852. doi: 10.1016/j.molmed.2019.05.009. Review. PubMed PMID: 31331739. 
  • Christophersen A, Lund EG, Snir O, Solà E, Kanduri C, Dahal-Koirala S, Zühlke S, Molberg Ø, Utz PJ, Rohani-Pichavant M, Simard JF, Dekker CL, Lundin KEA,Sollid LM, Davis MM. Distinct phenotype of CD4+ T cells driving celiac disease identified in multiple autoimmune conditions. Nat Med. 2019 May;25(5):734-737. doi: 10.1038/s41591-019-0403-9. PubMed PMID: 30911136.
  • Sollid LM, Jabri B. Triggers and drivers of autoimmunity: lessons from coeliac disease. Nat Rev Immunol. 2013 Apr;13(4):294-302. doi:10.1038/nri3407. Review. PubMed PMID: 23493116.
Published Mar. 13, 2018 11:38 AM - Last modified Apr. 11, 2022 2:22 PM